Entering China’s pharmaceutical market through M&A
Our client, a leading North American pharmaceuticals company, wanted to increase sales in China and obtain low cost production capacity to supply other markets. In a 10 week time frame we first developed acquisition criteria, identified and screened potential targets, for short listed targets we interviewed management, conduct preliminary due diligence and evaluated their interest in a strategic partnership.
A Chinese entrepreneur with world-class, IPR-protected technology?
Identifying emerging trends and determining how they will change competitive dynamics is key to successful commercial due diligence. In this case, a leading China-focused private equity firm needed help evaluating an investment into a Chinese company that claimed its homegrown, IPR-protected, technology could revolutionize an entire industry.
For private equity investors in China, commercial due diligence is essential in determining the risk/return profile of potential deals. In this case, our client needed to decide whether or not to proceed with an investment into a fast-growing Chinese agrochemicals company.